Open an account

PRF Technologies

PRFX · NASDAQ

$0.7246+$0.0109 (+1.53%)TodayMarket closed ·
Prev close $0.7137

About PRFX

PRF Technologies Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The company employs 6 full-time employees The company went IPO on 2020-09-01. The firm is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The firm also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.

Employees
4
Headquarters
TEL AVIV-YAFO
Listed
Sep 1, 2020
Sector
Health Care
Industry
Pharmaceuticals
Website
prf-tech.com

PRFX key statistics

Market cap
2.20M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
51.00K
Volume
1.70K
Open price
$0.75
High today
$0.7849
Low today
$0.7246
52 Week high
$7.95
52 Week low
$0.6912

PRF Technologies (PRFX) at a glance

As of Oct 21, 2026, PRF Technologies (PRFX) shares are priced at $0.7246, giving the company a market cap of 2.20M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.7246 and $0.7849. The current price is 0.0% above the day's low and 7.7% below its high.

Volume so far is 1.70K shares, below the average of 51.00K shares a day.

Over the past year PRF Technologies has ranged from $0.6912 to $7.95, and now sits 0% of the way up that range.

PRF Technologies met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY24 it reported -$213.60 per share against an estimate of -$127.30.

PRFX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 82.8% on average.

  1. Q2 FY21: reported -$192.00 per share against an estimate of -$624.24
  2. Q3 FY21: reported -$216.00 per share against an estimate of -$526.32
  3. Q4 FY21: reported -$206.40 per share against an estimate of -$673.20
  4. Q2 FY22: reported -$204.00 per share against an estimate of -$195.84
  5. Q3 FY23: reported $57.60 per share against an estimate of -$171.36
  6. Q4 FY23: reported -$373.20 per share against an estimate of -$182.38
  7. Q1 FY24: reported -$326.40 per share against an estimate of -$293.76
  8. Q2 FY24: reported -$213.60 per share against an estimate of -$127.30

PRFX news

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Lekha Gupta

    Consumer Tech News (May 25-29): Dell, IBM, CrowdStrike, Meta Lead Big Tech AI Push

  • Mohd Haider

    PRF Technologies (PRFX) Shares Surge Over 186% After Hours: Here's What Is Going On

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Vandana Singh

    EXCLUSIVE: PRF Technologies Advances Drop-Less Drug For Cataract Surgery Pain

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releasePRNewswire

    BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week

Similar companies

Companies in the same industry as PRF Technologies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.